Pharmaceutical Research, Development, And Launches Can Save Lives — And The Earth

The carbon footprint of the pharmaceutical industry is 55% higher than that of the automotive industry, and organizations are just starting to understand that an environmental, social, and governance (ESG) plan must include not only what goes on in their own processes but also what partners and contractors do. But as companies across the globe take steps to reduce their carbon footprint, pharmaceutical companies have the added challenges of a restrictive regulatory environment and a lack of cohesive ESG strategies.

The past three years in particular presented a number of challenges impacting the industry’s operating model and supply chain. The raw materials shortage and supply chain inconsistencies spurred by the pandemic led companies to source ingredients farther from factories and order in smaller batches, which — from a transportation and carbon footprint perspective — negatively affects the environment. Pressure on companies to accelerate development timelines and speed to market is also reducing the amount of time devoted to formulation, putting more burden on packaging materials to increase shelf stability.

Discover how having a defined framework and a defined way of measuring allows companies to align their priorities, short-term or long-term goals, and what ESG success looks like in terms of tangible measurements.